SALV.L

SalvaRx Group Plc
SalvaRx Group plc - Nominated Adviser Status
14th December 2018, 07:50
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5048K
SalvaRx Group plc
14 December 2018
 

 

14 December 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

 

Nominated Adviser Status

 

SalvaRx announces that the Directors have been advised by its current nominated adviser ("Nomad"), Northland Capital Partners Limited ("Northland"), of its proposed merger with SP Angel Corporate Finance LLP ("SP Angel").  Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7.00 a.m. on 1 February 2019.

 

As a result, it is the intention of the Directors to transition the Company's Nomad role from Northland to SP Angel.  This process has already started and at present the Directors anticipate a smooth and orderly transition of the Nomad role.

 

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence.  In accordance with AIM Rule 1, in the unlikely event that the Company fails to appoint a replacement Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities.  In the event that the Company has failed to appoint a replacement Nomad by 4 March 2019, the admission of its AIM Securities will be cancelled.

 

Enquiries:

 

SalvaRx Group plc


Ian Walters (Chief Executive)

Tel: +1 203-441-5451

Northland Capital Partners Limited

Nominated Adviser and Broker

Tel: +44 (0) 20 3861 6625

 

Matthew Johnson / Edward Hutton (Corporate Finance)


Vadim Alexandre (Corporate Broking)


Peterhouse Capital Limited

Joint Broker

Lucy Williams / Duncan Vasey

Tel: +44 (0) 20 7469 0932

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUSSBRWWAUARA ]]>
TwitterFacebookLinkedIn